On August 6, 2026 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reported financial results and business highlights for the second quarter ended June 30, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Second Quarter 2026 Financial Results
•Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025
◦HEPZATO KIT revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025
◦CHEMOSAT revenue of $2.0 million, compared to $1.7 million in the second quarter of 2025
•Gross margins of 90%, compared to 86% in the second quarter of 2025
•Net income of $2.7 million for both second quarters in 2026 and 2025
•Non-GAAP adjusted EBITDA of $7.6 million, compared to $9.8 million in the second quarter of 2025
•Cash provided by operations of $5.7 million in the quarter; compared to $7.3 million in the second quarter of 2025
•Cash and investments of $95.9 million as of June 30, 2026
Business Highlights
•Currently 31 active treatment centers
•Approximately 30% growth in HEPZATO volume in the second quarter 2026 compared to the second quarter 2025
•Independent investigators presented retrospective data at ESMO (Free ESMO Whitepaper) Breast Cancer 2026 showing a 60% hepatic partial response rate with percutaneous hepatic perfusion in heavily pretreated patients with liver-dominant metastatic breast cancer
•Independent investigators presented two investigator-initiated Trials-in-Progress abstracts at ASCO (Free ASCO Whitepaper) 2026: one evaluating sequential HEPZATO followed by tebentafusp in metastatic uveal melanoma, and one evaluating HEPZATO in combination with nivolumab/relatlimab in metastatic cutaneous melanoma with liver metastases
•Dosed the first patient in the global Phase 2 trial of HEPZATO in combination with standard of care in patients with liver-dominant HER2-negative metastatic breast cancer
"Our strong second quarter, including total revenue of $29.1 million and quarterly operating cash flow of $5.7 million, reflects continued momentum in HEPZATO procedures," said Gerard Michel, Chief Executive Officer of Delcath Systems. "As we grow our active treatment center network and drive physician adoption, we are seeing increased usage of HEPZATO in combination with systemic therapies to treat metastatic uveal melanoma. The growing clinical experience with this treatment strategy is strengthening physician confidence in HEPZATO and supporting its development as a multi-indication, liver-directed therapy platform, including colorectal and breast cancer."
2026 Full Year Financial Guidance
The Company’s financial outlook for fiscal year 2026:
•Total HEPZATO KIT and CHEMOSAT revenue to range from $104 million to $108 million, reflecting an increase in HEPZATO KIT volume of at least 28% over 2025
•Full year gross margins in the range of 86% to 89%
•Positive adjusted EBITDA
Second Quarter 2026 Results
Total revenue for the quarter ending June 30, 2026 was $29.1 million compared to $24.2 million for the same period in the prior year. Revenue in the quarter includes sales of $27.1 million of HEPZATO in the U.S. and $2.0 million of CHEMOSAT in Europe.
Research and development expenses for the quarter ending June 30, 2026, were $10.4 million compared to $6.9 million for the same period in the prior year. The increase is primarily due to increased clinical headcount and increased clinical trial activity.
Selling, general and administrative expenses for the quarter ended June 30, 2026, were $13.4 million compared to $11.4 million for the same period in the prior year. The increase is primarily due to continued commercial expansion activities.
Net income was $2.7 million for both the quarters ended June 30, 2026 and June 30, 2025.
Non-GAAP adjusted EBITDA for the quarter ended June 30, 2026 was $7.6 million compared to adjusted EBITDA of $9.8 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.
As of June 30, 2026, the Company had $95.9 million in cash and investments, and no debt.
Conference Call Information
To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.
Event Date: Thursday, August 6, 2026
Time: 8:30 AM Eastern Time
Participant Numbers:
Toll Free: 1-800-717-1738
International: 1-646-307-1865
Webcast: View Source;tp_key=cbc23b55c8
A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website View Source
(Press release, Delcath Systems, AUG 6, 2026, View Source [SID1234669792])